Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment

Journal of Alzheimer's Disease : JAD
Steffen WolfsgruberMichael Wagner

Abstract

There is very limited data on the prevalence of abnormal cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) and their predictive value for clinical progression in memory clinic patients with subjective cognitive decline (SCD). To assess the frequency of abnormal CSF biomarkers of AD and their predictive value for clinical progression in memory clinic patients with SCD in comparison to patients with mild cognitive impairment (MCI) from the same cohort. We analyzed prospective data from memory clinic patients of the German Competence Network Dementia cohort with a baseline diagnosis of SCD (n = 82) or MCI (n = 134), distinguished by actuarial neuropsychological MCI criteria ("Jak-Bondi criteria"). Risk of clinical progression during 3-year follow-up was evaluated with Cox-Proportional-Hazard models. Prevalence of abnormal values in CSF markers of tau-mediated neurodegeneration (67.8% versus 46.3%) but not of amyloid deposition (40.3% versus 35.4%) was significantly higher in MCI compared to SCD. The rate of incident AD dementia (26.1% versus 12.2%) was also significantly higher in MCI. In SCD, additional 22% progressed to MCI during follow-up. Combined amyloid/tau abnormality was the strongest predictor of clinical ...Continue Reading

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Aug 26, 1998·Dementia and Geriatric Cognitive Disorders·I HindmarchH Erzigkeit
Apr 6, 1999·Archives of Neurology·R C PetersenE Kokmen
Nov 13, 2003·Journal of Affective Disorders·Matthias J MüllerArmin Szegedi
Aug 25, 2004·Journal of Internal Medicine·R C Petersen
Jul 12, 2012·Archives of Neurology·Jennifer L WhitwellUNKNOWN Alzheimer Disease Neuroimaging Initiative
Dec 13, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Argonde C van HartenWiesje M van der Flier
Feb 5, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Frank JessenUNKNOWN German Study on Aging, Cognition and Dementia in Primary Care Patients
Sep 10, 2013·Lancet Neurology·Stephanie Jb VosAnne M Fagan
Sep 21, 2013·Neurology·Argonde C van HartenWiesje M van der Flier
Apr 12, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Flora H DuitsWiesje M van der Flier
May 7, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Frank JessenUNKNOWN Subjective Cognitive Decline Initiative (SCD-I) Working Group
May 20, 2015·JAMA : the Journal of the American Medical Association·Willemijn J JansenHenrik Zetterberg
Sep 16, 2015·JAMA : the Journal of the American Medical Association·Michael Wagner, Frank Jessen
Mar 26, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Bruno DuboisUNKNOWN Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclin
Oct 30, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Audrey PerrotinGaël Chételat
Nov 9, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·José L MolinuevoUNKNOWN Subjective Cognitive Decline Initiative (SCD-I) Working Group

❮ Previous
Next ❯

Citations

Nov 2, 2019·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Rachel F BuckleyRebecca E Amariglio
Jan 9, 2019·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Hanneke F M Rhodius-MeesterWiesje M van der Flier
Oct 15, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Leslie M ShawSheila Fifer
Apr 17, 2019·Alzheimer's Research & Therapy·Ingrid S van MaurikUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Aug 28, 2019·Brain Sciences·Elena ChipiLucilla Parnetti
Jul 4, 2018·Journal of Alzheimer's Disease : JAD·Claire PaquetJulien Dumurgier
Mar 23, 2018·Journal of Alzheimer's Disease : JAD·Harald HampelUNKNOWN Alzheimer Precision Medicine Initiative (APMI)
Jun 9, 2020·Frontiers in Neurology·Tong SiYing Han
May 23, 2019·Frontiers in Aging Neuroscience·Jadwiga Attier-ZmudkaOlivier Balédent
Jan 27, 2019·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·Frank Jessen
May 18, 2020·Journal of Alzheimer's Disease : JAD·Ferdinando PetrazzuoliSebastian Palmqvist
Mar 31, 2020·Clinics in Geriatric Medicine·Ryan D GreeneSophia Wang
Feb 4, 2021·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Mélanie BrissonJean-Paul Soucy
Jan 21, 2020·Lancet Neurology·Frank JessenMichael Wagner
Apr 2, 2021·International Journal of Geriatric Psychiatry·Adrià Tort-MerinoLorena Rami
May 19, 2021·Fortschritte der Neurologie-Psychiatrie·Ayda Rostamzadeh, Frank Jessen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.